Listen to Gynecologic Oncology

Editor's Choice:   Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice Hosted by:   Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring:   Jamie N. Bakkum-Gamez, MD; Department of...

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review Moderator: Ursula A. Matulonis, MD; Dana-Farber Cancer Institute Speakers: Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memo...

Editor's Choice:   Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection Hosted by:   Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring:   Surabhi Tewari, MD, Department of Obstetrics and Gynec...

Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Hosted by: Jose Alejandro Rauh-Hain, MD MPH Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Featuring: Charles A. Powell, MD, MBA Division of Pulmonary, Critical Care and Sleep Medicine, Tis...

Editor's Choice:  Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-sta...

Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA Chr...

Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is following up? Rethinking survivorship and surveillance Hosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United States Featuring: Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Cen...

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question? Hosted by: John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America Featuring: Steven Narod, Women's College R...

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer Editorial: Fro...

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Oliver Ziva...

Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S Editorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervic...

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms Hosted by: Jose Alejandro Rauh-Hain, MD, Associate Editor of Gynecologic Oncology Featuring: Larissa Alejandra Meyer, Department of Gynecologic Oncology a...

Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma Editorial: The search for new therapeutic options for uterine carcinosarcoma Hosted by: Amanda Nickles Fader, MD, Deputy Editor of Gynecologic Oncology Featuring: Britta Weigelt, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Sara Moufarrij, Gynecology S...

Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs Editorial: Diverting ileostomy: An ounce of prevention, but when? Hosted by: Diane Yamada, MD, Deputy Editor of Gynecologic Oncology Featuring: Anna Fagotti, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Ago...

Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study Editorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity Hosted by: Sean D...

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic...

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special...

Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival Editorial: Clinical trials are not the solution to inequities in cancer care Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Ashley Felix, PhD, MPH, Associate Professor, Division of Epidemiology. The Ohio State University College of Public Health Dav...

Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma Editorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic Oncology Featuring: Tullia Rushton, MD Beryl L. Manning-Geist, MD Check out more content on t...

Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study Editorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief! Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring:...

Editor’s Choice: Implementation of a financial navigation program in gynecologic oncology Editorial: Financial toxicity: moving from describing the problem toward developing interventions Hosted by: Diane Yamada, MD Featuring: Katharine M. Esselen, MD Margaret Liang, MD Check out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment? Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Mohamed Elshaikh, MD...

Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva Editorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, Canada Dr Bren...

Editor's Choice: 2023 FIGO staging system for endometrial cancer: The evolution of the revolution Editorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coin Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology  Featuring: Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USA Dr. David Gaffney, MD-PhD, University of...

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists Editorial: Who you gonna call? Hosted by: David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter Health Connor C. Wang, MD, Northwestern University Feinberg School of Medic...